Novo Nordisk (NVO) Gets Downgraded to Neutral from Buy at UBS

Novo Nordisk A/S (NYSE:NVO) is one of the top NYSE stocks with the highest upside potential. On August 5, UBS downgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Buy, bringing the price target down to DKK 340 from DKK 600.

Novo Nordisk A/S (NVO): "Canada's A Backdoor," Says Jim Cramer

An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.

The firm told investors in a research note that it sees “challenging times” for Novo Nordisk A/S (NYSE:NVO), with its analysis showing that the US compounding of weight loss drugs is “here to stay.” UBS added that this brings an uncertain outlook for Novo Nordisk A/S’ (NYSE:NVO) Wegovy.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products.

Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.